KE

Kimball Electronics, Inc. (KE) - Q3 2025 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended March 31, 2025 (Fiscal Q3 2025) and the nine months ended March 31, 2025. Kimball Electronics is a global provider of electronics manufacturing services (EMS) and contract manufacturing organization (CMO) solutions serving automotive, medical, and industrial markets. The company recently completed the divestiture of its GES business in July 2024 and announced a plan to cease operations at its Tampa facility.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Net sales decreased 12% in Q3 and 14% YTD compared to the prior year. This was driven by a loss of a major automotive program, the divestiture of the GES business, and declines in the industrial sector (smart metering and public safety).
• Margin Compression: Gross margin declined to 7.2% in Q3 (from 7.9% prior year) due to lost absorption on lower revenue and dilution from a non-recurring consignment inventory sale in the medical sector.
• Restructuring Costs: Restructuring expenses increased to $2.0 million in Q3 (vs. $1.6 million prior year) and $9.0 million YTD (vs. $1.6 million prior year). This includes costs for workforce resizing and the Tampa facility closure plan.
• One-Time Items: The prior year included $5.8 million in goodwill impairment and $16.6 million in asset impairment charges related to the GES divestiture decision, which were not present in the current period. The current period included a $1.3 million gain on the disposal of GES.
• Interest Expense: Interest expense decreased significantly (Q3: $2.9M vs $5.9M prior year) due to lower borrowings and interest rates.

Guidance, Outlook, and Risks

• Outlook: Management expects consolidated net sales to continue to lag compared to fiscal year 2024 through calendar year 2025 due to the lost automotive program, GES divestiture, and impacts from an FDA recall affecting a major medical customer.
• Restructuring: The Tampa facility closure is expected to be completed by the end of fiscal year 2025. Total exit costs are estimated between $6.5 million and $8.5 million, with an additional $3 million to $4.5 million in pre-tax restructuring charges expected for the remainder of the year.
• Liquidity: The company maintains a strong balance sheet with $304.6 million in short-term liquidity (cash plus unused credit facilities). A new $100 million term loan was added to the credit facility in December 2024.
• Risks: Key risks include global economic conditions, supply chain constraints, foreign exchange fluctuations, and the ability to replace expiring customer programs. The company is also subject to potential tax liabilities if foreign earnings are repatriated.

Investor Verification Checklist

• Automotive Program Loss: Verify the specific impact and duration of the lost major automotive program on future revenue streams.
• Tampa Closure Execution: Monitor the timeline and actual costs associated with the Tampa facility closure and the transfer of production to other sites.
• Medical Sector Recovery: Assess the resolution of the FDA recall impacting the major medical customer and the sustainability of medical sales excluding the non-recurring consignment inventory.
• Working Capital Trends: Track the improvement in Cash Conversion Days (CCD) as the company aligns inventory and receivables with lower sales levels.
• Debt Covenants: Confirm continued compliance with the amended credit facility covenants, specifically the leverage ratio and interest coverage ratio.